The results reported here demonstrate that ERAS acts as a true oncogene in mammary glands and suggest that ERAS could be implicated in any of the RASopathies and/or overgrowth syndromes of unknown genetic origin. The gene discussed is ERAS; the disease is overgrowth syndrome.